We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-1.2%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$212M
Cap. Flow
-$139M
Cap. Flow %
-25.42%
Top 10 Hldgs %
37.58%
Holding
232
New
36
Increased
20
Reduced
48
Closed
92

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$11.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.51M
3
UTHR icon
United Therapeutics
UTHR
+$8.13M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.75M
5
ALT icon
Altimmune
ALT
+$5.53M

Top Sells

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$21M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$9.33M
3
SAGE
Sage Therapeutics
SAGE
+$8.38M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.11M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 43.2%
2 Technology 0.14%
3 Consumer Staples 0.03%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
176
MacroGenics
MGNX
$233M
– –
-164,119
Closed -$1.45M
MXCT icon
177
MaxCyte
MXCT
$108M
– –
-137,958
Closed -$964K
NBIX icon
178
CALL
Neurocrine Biosciences
NBIX
$18.2B
– –
-429,600
Closed -$40.3M
NKTR icon
179
CALL
Nektar Therapeutics
NKTR
$2.39B
– –
-8,927
Closed -$722K
NRSN icon
180
NeuroSense Therapeutics
NRSN
$17.3M
– –
-100,000
Closed -$397K
NTLA icon
181
Intellia Therapeutics
NTLA
$1.51B
– –
-47,408
Closed -$3.44M
NUVB icon
182
Nuvation Bio
NUVB
$2.29B
– –
-213,310
Closed -$1.12M
NVAX icon
183
Novavax
NVAX
$1.21B
– –
-1,362
Closed -$100K
OCUL icon
184
Ocular Therapeutix
OCUL
$1.83B
– –
-29,644
Closed -$147K
PASG icon
185
Passage Bio
PASG
$14.5M
– –
-3,593
Closed -$223K
PBYI icon
186
Puma Biotechnology
PBYI
$398M
– –
-49,843
Closed -$144K
PDSB icon
187
PDS Biotechnology
PDSB
$37.4M
– –
-3,672
Closed -$22K
PHAT icon
188
Phathom Pharmaceuticals
PHAT
$928M
– –
-78,550
Closed -$1.07M
PLRX icon
189
Pliant Therapeutics
PLRX
$65M
– –
-90,805
Closed -$636K
PMVP icon
190
CALL
PMV Pharmaceuticals
PMVP
$57.1M
– –
-100,000
Closed -$2.08M
PMVP icon
191
PUT
PMV Pharmaceuticals
PMVP
$57.1M
– –
-100,000
Closed -$2.08M
PTGX icon
192
CALL
Protagonist Therapeutics
PTGX
$8.55B
– –
-160,700
Closed -$3.81M
QSI icon
193
Quantum-Si Incorporated
QSI
$153M
– –
-157,363
Closed -$736K
RLMD icon
194
Relmada Therapeutics
RLMD
$540M
– –
-21,801
Closed -$476K
SAGE
195
DELISTED
Sage Therapeutics
SAGE
– –
-249,907
Closed -$8.38M
SLDB icon
196
Solid Biosciences
SLDB
$792M
– –
-34,744
Closed -$625K
SLNO
197
DELISTED
Soleno Therapeutics
SLNO
– –
-8,564
Closed -$29K
SVRA icon
198
Savara
SVRA
$1.08B
– –
-1,622,552
Closed -$2.13M
TENX icon
199
Tenax Therapeutics
TENX
$393M
– –
-459
Closed -$596K
TGTX icon
200
TG Therapeutics
TGTX
$8.19B
– –
-2,292
Closed -$21K
6 7
8
9 10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Ikarian Capital held 232 positions worth $548M, down 28% from $760M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital withdrew a net $139M in Q2 2022, closing 92 positions and reducing 48 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in Esperion Therapeutics worth $13.1M.

  • Ikarian Capital's largest Q2 2022 buy was Esperion Therapeutics: 2,054,602 shares worth $13.1M.
  • Ikarian Capital added most to Alnylam Pharmaceuticals in Q2 2022, an estimated $8.51M increase.
  • Ikarian Capital's biggest Q2 2022 reduction was Adicet Bio, cutting an estimated $5M.
  • Ikarian Capital fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $21M.
  • Ikarian Capital's ten largest holdings make up 38% of its $548M portfolio in Q2 2022.
  • Ikarian Capital opened 36 new positions and closed 92 in Q2 2022.
  • Ikarian Capital's portfolio value fell 28% quarter-over-quarter to $548M.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.